会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 51. 发明申请
    • Methods and apparatuses for repairing aneurysms
    • 修复动脉瘤的方法和装置
    • US20070038288A1
    • 2007-02-15
    • US10521063
    • 2003-07-11
    • Whye-Kei LyeMichael ReedMark Wholey
    • Whye-Kei LyeMichael ReedMark Wholey
    • A61F2/06A61F2/90
    • A61F2/07A61F2/064A61F2/848A61F2/91A61F2/915A61F2002/067A61F2002/072A61F2002/075A61F2002/91533A61F2002/91575A61F2220/0008A61F2220/0016
    • Apparatuses, systems and methods are provided for repairing aneurysms in the vasculature of a patient. An aneurysm is repaired by positioning a tube or graft within the vasculature, extending through the region of the aneurysm to provide a blood flow conduit similar to the native vasculature. The tube is held in place within the vasculature by at least one expandable body having at least one microstructure. The microstructures are attached to the expandable body in a low profile fashion suitable for atraumatic introduction to the vasculature with the use of a catheter or other suitable device. Each microstructure has an end which is attached to the expandable body and a free end. Once the apparatus is positioned within the vasculature in the desired location, the one or more of the microstructures are deployed so that the free ends project radially outwardly. The free ends of the deployed microstructures then penetrate the blood vessel wall by continued expansion of the body for anchoring, reduction or migration or leakage and/or drug delivery.
    • 提供了用于修复患者脉管系统中的动脉瘤的装置,系统和方法。 通过将管或移植物定位在脉管系统内,延伸穿过动脉瘤的区域来修复动脉瘤,以提供类似于本地脉管系统的血流导管。 通过具有至少一个微结构的至少一个可膨胀体将管保持在脉管系统内的适当位置。 微结构以适于使用导管或其它合适的装置对脉管系统进行无损伤引入的低调方式附着到可膨胀体上。 每个微结构具有连接到可膨胀体的端部和自由端。 一旦将装置定位在期望位置的脉管系统内,则一个或多个微结构被展开,使得自由端径向向外突出。 部署的微结构的自由端然后通过身体的持续膨胀而穿过血管壁,用于锚固,减少或迁移或渗漏和/或药物递送。
    • 53. 发明申请
    • Stent with nanoporous surface
    • 支架纳米孔表面
    • US20060271169A1
    • 2006-11-30
    • US11432281
    • 2006-05-11
    • Whye-Kei LyeKareen LooiMichael Reed
    • Whye-Kei LyeKareen LooiMichael Reed
    • A61F2/82A61F2/28
    • A61L31/146A61F2/86A61L31/082A61L31/16A61L2300/41A61L2300/416Y10S623/901Y10T428/12458
    • Methods for fabricating a medical device having at least one porous layer include providing a medical device having at least one alloy and removing at least one component of the alloy to form the porous layer. Although methods may be used to make stent devices with porous layers, any other suitable medical device may be made having one or more porous layers. An alloy may include any suitable combination of metals and sometimes a combination of metal and non-metal. In some embodiments, one or more of the most electrochemically active component(s) of an alloy are removed by the dissolving (or “dealloying”) process, to leave a porous matrix behind. The porous matrix layer may then be infused with one or more therapeutic agents for enhancing treatment of a patient.
    • 制造具有至少一个多孔层的医疗装置的方法包括提供具有至少一种合金的医疗装置,并除去合金的至少一种成分以形成多孔层。 虽然可以使用方法来制备具有多孔层的支架装置,但是可以制造具有一个或多个多孔层的任何其它合适的医疗装置。 合金可以包括任何合适的金属组合,有时是金属和非金属的组合。 在一些实施方案中,通过溶解(或“脱模”)方法除去合金中最大的电化学活性组分中的一种或多种,​​以留下多孔基体。 然后可以用一种或多种用于增强患者治疗的治疗剂注入多孔基质层。
    • 56. 发明申请
    • Compound
    • 复合
    • US20060074060A1
    • 2006-04-06
    • US11234868
    • 2005-09-23
    • Nigel VickerHarshani LawrenceGillian AllanChristian BubertDelphine Sophie FischerAlan PurohitMichael ReedBarry Victor Potter
    • Nigel VickerHarshani LawrenceGillian AllanChristian BubertDelphine Sophie FischerAlan PurohitMichael ReedBarry Victor Potter
    • A61K31/58C07J71/00
    • C07J71/00C07J41/00
    • There is provided a compound of Formula (I) wherein (I) R2 is selected from (i) an alkyloxyalkyl group (ii) a nitrile group, and wherein R2 is capable of forming a hydrogen bond (iii) alkylaryl group, wherein the aryl group is substituted by other than a C1-10 group (iv) alkenylaryl group wherein the aryl group is substituted (v) alkylheteroaryl group, wherein when heteroaryl group comprises only C and N in the ring, the aryl group is substituted by other than a methyl group (vi) alkenylheteroaryl group, (vii) ═N—O-alkyl or ═N—O—H group (viii) branched alkenyl (ix) alkyl-alcohol group (x) amide or alkylamide wherein (a) the alkyl of the alkylamide is —CH2— or —Ch2Ch2—, (b) the amide is di-substituted and/or (c) the amide is substituted with at least one of alkyl heterocycle group, alkenyl heterocycle group, alkylheteroaryl group, alkenylheteroaryl group, heteroaryl group, alkylamine group, alkyloxyalkyl group, alkylaryl group, straight or branched alkyl group, (xi) —CHO so that R1 together with R3 provide the enol tautomer (a); OR R2 together with R3 form (xii) a pyrazole wherein (a) R4 is ═N—O-alkyl or ═N—O—H group, (b) the pyrazole is substituted with one of alkyl-OH group, alkyl ester group, alkyloxyalkyl group, branched alkyl group, and an amide and/or (c) the 2 position is substituted with a group selected from —OH and —O-hydrocarbyl (xiii) a heteroaryl ring to provide a compound of the formula (b); (II) R2 is selected from groups capable of forming a hydrogen bond, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group and a sulphonamide group; and (III) R3 is selected from —OH, ═O, or a C(═O)—mimetic.
    • 提供式(I)化合物,其中(I)R 2选自(ⅰ)烷氧基烷基(ⅱ)腈基,其中R2能够形成氢键(ⅲ)烷基芳基,其中芳基 基团被取代的芳基(ⅴ)烷基杂芳基以外的C 1-10基团(ⅳ)链烯基芳基取代,其中当杂芳基仅在环中仅包含C和N时,芳基被除了 甲基(vi)烯基杂芳基,(vii)-NO-烷基或-NOH基(viii)支链烯基(ix)烷基 - 醇基(x)酰胺或烷基酰胺,其中(a)烷基酰胺的烷基是-CH2- 或-C 2 -C 12 - ,(b)酰胺是二取代的和/或(c)酰胺被烷基杂环基,烯基杂环基,烷基杂芳基,烯基杂芳基,杂芳基,烷基胺基,烷氧基烷基中的至少一个 基团,烷基芳基,直链或支链烷基,(xi)-CHO,使得R1起始 与R3提供烯醇互变异构体(a); OR 2与R 3一起形成(xii)吡唑,其中(a)R4是-NO-烷基或-NOH基,(b)吡唑被烷基-OH基,烷基酯基,烷氧基烷基,支链烷基 基团和酰胺和/或(c)2位被选自-OH和-O-烃基(xiii)杂芳基环的基团取代,以提供式(b)的化合物; (II)R2选自能够形成氢键的基团,氨基磺酸酯基,膦酸酯基,硫代膦酸酯基,磺酸酯基和磺酰胺基; 和(III)R 3选自-OH,-O或C(-O) - 模仿物。